Vimarsana
Biggest News Aggregation in the World

Chipscreen Newway News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chipscreen Newway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chipscreen Newway Today - Breaking & Trending Today

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors - Vimarsana News

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

Published: January 16, 2024

/PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that on January 5, 2024, the dosing of the first patient for a phase I...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesSan FranciscoChipscreen Newway BiosciencesChipscreen NewwayHaimen JiangsuChipscreen BiosciencesChipscreen Biosciences United StatesShenzhen Chipscreen Pharmaceuticals Co LtdShanghai Business CenterBiocytogen Pharmaceuticals Beijing Co LtdPrnewswire Chengdu Chipscreen Newway Biosciences Co LtdShenzhen Chipscreen Biosciences Co LtdSun Yat Sen University Cancer CenterChengdu Chipscreen Pharmaceuticals Co LtdEucure Beijing Biopharma Co LtdChengdu Chipscreen Newway Biosciences Co LtdClinical Research CenterBin LiuScientific DirectorGreater ChinaMainland ChinaChengdu Hi Tech ZoneGenomics Based Integrated Drug DiscoveryEarly Evaluation
Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences' Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008 - Vimarsana News

Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences' Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

Published: February 27, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd.

Source: businesswireindia.com
Related Topics:
United StatesHong KongBaden WübergHaimen JiangsuChipscreen Newway BiosciencesChipscreen BiosciencesYuelei ShenEucure BiopharmaChipscreen NewwayXianping LuEucure Beijing Biopharma Co LtdDrug AdministrationBiocytogen Pharmaceuticals Beijing Co LtdHead Of The CenterShenzhen Chipscreen Biosciences Co LtdGreater ChinaMainland ChinaBin LiuFc Silent IggChina FoodChengdu Hi Tech ZoneMedia ContactBiocytogen PharmaceuticalsIocytogen Pharmaceuticals Beijing Co Eucure Biopharma